Rx Medicare

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) announced the results of its recently completed North American Phase III clinical trial for its twice-daily formulation of tramadol and acetaminophen (study 06CCL3-001). Study 06CCL3-001 was a multi-centre, randomized, double-blind, parallel-arm study that compared the efficacy and safety of Labopharm’s twice-daily tramadol-acetaminophen formulation to placebo in the treatment of moderate to severe acute low back pain.

Read More…

Related Posts

• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• Alkermes Announces Positive Results For Phase 1 Study Of New Drug Candidate For Treatment Of Opioid-Induced Constipation
• Phosphagenics Announces Positive Results From Phase 1B Study Of Transdermal Oxycodone Patch
• AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural Sedation, Anxiolysis & Analgesia
• BioElectronics Announces Results From Pilot Section Of Acetaminophen Comparative Study
• Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)
• Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study For The Treatment Of Postherpetic Neuralgia (PHN)
• AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
• BEMA Buprenorphine To Proceed To Phase 2 Following Favorable Initial Study Results
• Nektar Announces Positive Results From Phase 2 Study Of Oral NKTR-118 In Patients With Opioid-Induced Constipation (OIC)
• SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
• QRxPharma Initiates Second Pivotal Phase 3 Study Of MoxDuo(TM)IR Dual-Opioid(TM) For NDA Submission
• Trigemina Conducting Phase IIa Clinical Trial In Chronic Daily Headache
• Protecting Patients: Study Shows That Johns Hopkins Flu Vaccination Rates Are Twice The National Average
• SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine

Tags: acetaminophen, daily, formulation, labopharm, phase, results, study, tramadol, twice

This entry was posted on Friday, April 3rd, 2009 at 7:04 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.